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Sarcomas are rare heterogeneous malignancies of mesenchymal origin characterised by complex karyotypes but no speciﬁc
abnormalities. Recurrence is common, and metastatic disease carries poor survival despite standard DNA-damaging radiotherapy
or chemotherapy. DNA double-strand breaks (DSBs) are either repaired bymechanisms such as homologous recombination (HR)
or result in cell death by apoptosis. Endogenous cH2AX formation and SCE formation are early and late events, respectively, and
their levels are considered surrogate measures of genomic instability. Combined cH2AX and SCE analysis was used to evaluate
endogenous DNA DSB levels (and their subsequent repair) in 9 primary sarcoma cell lines and compared with well-established
commercial lines. All the sarcoma cell lines had elevated cH2AX and SCE levels, but there was no correlation between the DNA
DSB frequency and subsequent SCE. Typically, radioresistant osteosarcoma cells had relatively low cH2AX frequency but high
SCE counts suggestive of eﬃcient DNA repair. Conversely, liposarcoma cells derived from a radiosensitive tumour had high
H2AX but relatively lower SCE levels that may imply ineﬃcient DNA DSB repair. To our knowledge, this is the ﬁrst report that
correlates H2AX and SCE levels in primary sarcoma cell lines and may provide insight into potential response to DNA-
damaging treatments.
1. Introduction
Soft tissue sarcomas (STSs) are a group of rare, heterogeneous
malignancies of mesenchymal origin that aﬀect around 2300
people a year in the UK [1]. *ey comprise less than 1% of all
cancer diagnoses among adults but pose a signiﬁcant diag-
nostic challenge with over 22 diﬀerent subtypes and over 100
distinct morphologies (ICD-10) [2]. Current treatment rec-
ommendations for localised disease mainly involve a combi-
nation of surgery and radiotherapy in most subtypes, with
chemotherapy reserved for a few sensitive subtypes [3, 4].
Overall survival for localised disease is in the order of 50–60%
at 5 years but with metastatic disease, and two-year survival is
only 20–30%with amedian survival of around 12months with
standard chemotherapy [5].
STSs fall into one of two large genomic classes: *e ﬁrst
is characterised by known, speciﬁc abnormalities such as
chromosomal translocations or gene mutations and com-
prises around 20% of STSs. *e majority of sarcomas, on the
other hand, are characterised by complex seemingly random
DNA copy number aberrations across the entire genome.
*ey have no known speciﬁc abnormalities (a notable ex-
ception is well-diﬀerentiated liposarcomas that frequently
carry chromosome 12q ampliﬁcation), and their complex
karyotypes are believed to be the result of genomic in-
stability, a hallmark of the cancer phenotype [6].
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Sister chromatid exchange (SCE) analysis is a method
that allows the physical quantication of exchanged genetic
material between sister chromatids during in vitro mitosis.
Considered an endpoint of DNA repair by homologous
recombination, measurement of SCE is a well-established
and sensitive method for detecting DNA damage in the form
of double-strand breaks (DSBs) induced by genotoxic agents
[7–9]. e current method for SCE analysis developed by
Perry andWol uses the thymidine substitute, 5′-bromo-2′-
deoxyuridine (BrdU), which is incorporated into the DNA
over two consecutive cell cycles creating an imbalance in the
amount of BrdU in each sister chromatid [10]. Once stained,
a harlequin banding pattern can be observed and the ex-
change of genetic material can be visualised as a mismatch
between dark and lighter chromatids (Figure 1). e fre-
quency of SCE can thus be enumerated in metaphase
chromosome spreads prepared from cells toward the end of
the second mitosis following BrdU treatment.
An even earlier event in the DNA DSB repair process is
the phosphorylation of the histone molecule H2AX at serine
139 to cH2AX, which accumulates at the sites of damage and
recruits other DNA repair proteins. Phosphorylation of the
histone protein H2AX is well recognised as an early step in
the cellular recognition of DNA DSB for subsequent repair
[11]. Using phospho-specic antibodies, cH2AX foci at sites
of DNA damage can be visualised and enumerated as an-
other measure of DNA repair in eukaryotic cells [12].
Spontaneous SCE and cH2AX formation has been observed
in human cells where they are believed to be the result of
endogenous DNA damage that causes collapsed replication
forks and DNA double-stand breaks (DSBs) during mitosis.
e frequency of endogenous DNA DSB repair has,
therefore, been widely used as a surrogate measure of ge-
nomic instability in these cells [13, 14].
Unlike cH2AX analysis which is done on interphase
chromosomes, the specic timing requirement of metaphase
spread preparation for SCE analysis makes this method
technically challenging, and the majority of published
studies utilising SCE analysis have focused on peripheral
blood lymphocytes, which have relatively predictable dou-
bling time. e observed frequency of endogenous SCE in
normal human tissue and peripheral blood lymphocytes
(PBLs) is around 6–8 per cell [15, 16]. Elevated frequency of
SCE has been observed in PBL of patients with breast,
prostate, gastric, ovarian, and cervical cancers showing up to
three times the normal SCE frequency [13]. Individuals with
Bloom’s syndrome, a familial cancer-predisposing disease,
also have remarkably high SCE frequency in their PBL [17],
(a) (b)
(c) (d)
Figure 1: Endogenous sister chromatid exchanges and cH2AX foci in sarcoma cells. (a) Harlequin-stained metaphase chromosomes from
a Shef-DDLPS 02 (dedierentiated liposarcoma) cell showing a hyperdiploid karyotype with over 120 chromosomes. (b) Higher mag-
nication of a section of the same metaphase chromosome spread showing nine sister chromatid exchanges (red arrows). (c) Interphase
nuclei of hTERT-RPE1 (human retinal epithelium) cells showing <10 endogenous cH2AX foci each (red dots). (d) Shef-DDLPS 02 cell
nucleus showing >10 cH2AX foci (red dots). Metaphase chromosomes were stained with Hoechst 33258 dye followed by exposure to UV
light. Interphase nuclei were stained using Cy3-conjugated rabbit anti-cH2AX antibody and counterstained blue with DAPI.
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with an average of 89 per diploid cell [18]. Subsequent
studies exploring the association between elevated PBL SCE
frequency and cancer, however, showed mixed results and
suggested a generalised increase in genetic instability but no
speciﬁc links to tumour initiation or biomarker development
[19–22].
SCE data on cancer cells are derived largely from hae-
matologic malignancies, such as leukaemia, where tumour
cells are prominent in the circulation [23] while only
a handful of studies have been published based on established
and commercially available solid organ tumour cell lines
[13, 24–26].With the exception of uvealmelanomas [13], these
have all shown that tumour cells possess elevated SCE fre-
quency in keeping with genetic instability as a hallmark of
cancer. Unfortunately, there is poor representation of STSs
among commercially available cell lines, with the majority
being translocation-driven subtypes. Furthermore, the limi-
tations of commercial cell lines as an in vitro disease model are
increasingly being recognised. Cellular adaptation with pro-
longed culture in artiﬁcial conditions and a lack of cellular
heterogeneity that is characteristic of in vivo tumours are
important factors that are believed to account for poor cor-
relation of tumour cell line response with clinical outcomes. To
ameliorate these important limitations, a widely accepted al-
ternative to commercial cell lines is those directly derived from
tumours (primary tumour cells) in early culture with less
adaptation to artiﬁcial conditions. Ethical and logistic con-
straints associated with obtaining fresh tumour tissue (typi-
cally within minutes of surgery or biopsy), variable rates of
successful establishment in culture and unpredictable sub-
sequent in vitro behaviour make it rather challenging to utilise
them for research in general and SCE analysis in particular.
In this study, we assessed endogenous genomic DNA
damage/repair in a cohort of primary STS cell lines repre-
senting a range of subtypes. *e frequency of early and late
endogenous DNA DSB repair was measured using cH2AX
and SCE, respectively, as surrogates for genomic instability
and compared to those observed in long-established,
commercially available sarcoma cell lines, low SCE tu-
mour cells, and nontumour cells.
2. Materials and Methods
2.1. Cell Lines and Cultures. Primary STS cell lines were
developed from patient samples collected at the Royal
Hallamshire Hospital, Sheﬃeld, as previously described
[27]. Informed consent was obtained from each patient after
ethical approval (reference number 09/H1313/52), and tissue
samples were handled in accordance with research ethics
guidelines and the Human Tissue Act 2004. Short tandem
repeat (STR) proﬁling was used to conﬁrm the identity of all
cell lines included in this study [27]. *e sarcoma cell lines
SOM-196b and hTERT-RPE1 were maintained in culture as
previously described [13, 27] and subcultured as required.
2.2. Sister Chromatid Exchange Analysis. SCE analysis was
performed as previously described [13]. Cell cultures were
incubated with 0.24 µM 5′-bromo-2′-deoxyuridine (BrdU)
for approximately two cell cycles. *is duration varied be-
tween 3 and 7 days depending on the proliferation rate of the
cells, and multiple attempts were required to identify the
required duration, particularly for the primary cell lines. Cell
cycling was arrested in metaphase by addition of 10 µg/ml
colcemid and incubating for 2–4 hours (*ermo Fisher
Scientiﬁc®, Paisley, UK). Chromosomes were then harvested
by trypsinization and centrifuged and resuspended in
0.075M potassium chloride (KCl) at 37°C for 40 minutes
before ﬁxing in a 3 :1 methanol to acetic acid solution.
Metaphase chromosome spreads were prepared on cold wet
slides before staining with an adapted Perry and Wolﬀ
method with incubation in Hoechst 33258 dye for 15
minutes and exposure to UV-light for 12 minutes. Stained
metaphases were visualised with a BH-2 light microscope,
and images were captured with a Cohu® high-performance
CCD camera (Cohu Electronics, San Diego CA, USA) and
Powergene® software (Applied Imaging, Santa Clara, CA,
USA). *e number of chromosomes and exchanges in each
metaphase spread was recorded. Chromosomes that were
clearly overlapping or twisted were excluded from the ex-
change count, as is consistent with previous reports.
SCE counts were performed on up to 30 harlequin-
stained metaphase chromosome spreads (Figure 1) where
available. However, due to technical diﬃculties with the
harlequin staining technique, it was not always possible to
obtain a suﬃcient number of metaphase chromosome
spreads from a single culture and chromosome harvest. In
these cases, SCE analysis was repeated at a subsequent
culture passage in order to obtain suﬃcient numbers
(Table 1). For primary sarcoma cell lines, a minimum of ten
analysed metaphase spreads was required for inclusion in
this study.
2.3. cH2AX Assay. Analysis of cH2AX foci formation was
again performed as previously described [13]. Viable cells
were seeded at a density of 20,000 each on glass coverslips
placed in six-well plates and cultured overnight. *e cells
were then washed with ice-cold phosphate-buﬀered saline
(PBS) before ﬁxing with 3% paraformaldehyde. *ey were
then rinsed with PBS and permeabilised with 0.2% Triton-X
for 5 minutes before blocking with 10% goat serum for 1
hour. Following another brief wash with PBS, the cells were
incubated at 4°C overnight in the dark with Cy3-conjugated
rabbit anticH2AX antibody (Cell Signaling Technologies®,
Danvers, MA, USA) diluted 1 : 500 in 10% goat serum in
PBS. Cells were subsequently washed on a shaker with PBS,
and the coverslips were inverted onto microscope slides and
mounted with Vectashield containing DAPI (Vector®,
Peterborough, UK). Slides were stored in the dark at 4°C, and
the number of foci per nucleus in 100 cells was counted on
a UV spectrum-red ﬂuorescent Nikon image analysis mi-
croscope at 100x magniﬁcation.
3. Results
3.1. Endogenous SCE Levels in Sarcoma Cell Lines. Nine
primary cell lines, representing four soft tissue sarcoma
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subtypes, were analysed for SCE (Table 1). Two of these are
morphologically distinct cultures that represent separate
tumour cell clones (variants) derived from a single leio-
myosarcoma, as we have previously demonstrated [27]. *e
four established and commercially available sarcoma cell
lines U-2 OS, SK-LMS-1, SK-UT-1, and SW-1353, all of
which are known to have complex karyotypes and high levels
of endogenous SCE [13], were analysed as high-SCE con-
trols. A nontumour cell line, hTERT-RPE1, and a uveal
melanoma cell line, SOM-196b, previously shown to possess
low SCE levels [13] were used as normal and low SCE
controls, respectively.
Tumour cells were frequently hyperdiploid with signif-
icant inter- and intratumour heterogeneity in terms of
chromosome number (Figure 1 and Table 1). To account for
this heterogeneity and facilitate accurate comparison with
normal diploid cells, the number of exchanges visualised per
metaphase spread was normalised for a diploid (2n) kar-
yotype by multiplying observed SCE by 46 and then dividing
by the observed chromosome number.
3.2. Elevated Endogenous SCE Levels in Primary Sarcoma Cell
Lines. *e control cell lines SOM-196b and hTERT-RPE1
had median SCE counts of 6 and 8 per diploid (2n)
metaphase spread, respectively, as expected (Figure 2).
Certain factors are known to potentially confound the results
of endogenous SCE analysis in cultured cells. For example,
BrdU that is used to substitute thymidine residues in DNA
and required for harlequin staining pattern of sister chro-
matids for analysis is known to be genotoxic and can result
in slightly increased SCE frequency of around 1–3 per
metaphase [28–30]. Furthermore, it has been demonstrated
that certain media supplements (such as antibiotics or se-
rum) can induce SCE in cultured cells in vitro [31, 32]. In
order to minimise these eﬀects, the lowest BrdU concen-
tration (0.24M) that produced satisfactory banding was used
in all experiments [13], and normal cell line controls were
cultured using identical media and supplements as the
primary sarcoma cells prior to SCE analysis. *e normal
control cell line demonstrated the SCE level that was within
the expected range of 6–8 per metaphase spread, suggesting
that these potential artefacts if present had minimal eﬀect on
our results.
All four commercially available sarcoma cell lines had
endogenous SCE levels that were well above the expected
normal range of 6–8, with median SCE counts of 15–31 per
2n metaphase spread (Table 1). Among these, it was notable
that the osteosarcoma cell line U-2 OS had SCE levels (31 per
2n metaphase spread) that were nearly double those seen
among the other sarcoma cell lines (Figure 2). SCE levels
observed in the primary sarcoma cell lines were similar to
Table 1: Endogenous sister chromatid exchange in sarcoma cell lines.
Cell line Histological subtype Passagenumber
Number of
metaphases
Chromosome count,
median (range)
Median SCE count Range
Observed aNormalised
Nontumour/low SCE
controls
hTERT-RPE1 Normal retinalepithelium 7 43 (31–48) 8 8 6–13
SOM-196b Uveal melanoma 11 45 (34–46) 6 6 1–14
Commercially available
sarcoma cell lines
U-2 OS Osteosarcoma 30 71 (64–76) 47 31 17–63
SK-LMS-1 Leiomyosarcoma 10 100 (86–151) 42 18 14–37
SK-UT-1 Uterineleiomyosarcoma 20 44 (32–48) 14 15 8–31
SW-1353 Chondrosarcoma 12 48 (45–53) 17 16 9–20
Primary sarcoma cell lines
Shef-UPS 01 Undiﬀerentiatedpleomorphic sarcoma p69 22 59 (44–67) 13 10 7–18
bShef-UPS 02 Undiﬀerentiatedpleomorphic sarcoma
p15 10 60 (56–60) 23 17 10–27
p30 7 89 (53–114) 24 16 7–30
bShef-UPS 03 Undiﬀerentiatedpleomorphic sarcoma
p17 29 56 (47–60) 23 18 9–33
p33 24 71 (50–126) 23 17 9–32
bShef-UPS 04 Undiﬀerentiatedpleomorphic sarcoma
p3 12 60 (51–65) 20 16 8–25
p8 30 59 (52–69) 20 15 7–30
Shef-DDLPS 01 Dediﬀerentiatedliposarcoma p70 29 76 (41–97) 22 13 7–21
b,cShef-DDLPS 02 Dediﬀerentiatedliposarcoma
p12 30 108 (51–154) 35 14 9–25
p23 29 117 (52–151) 33 13 7–26
Shef-LMS 01 w1 Leiomyosarcoma p51 25 127 (74–152) 28 10 8–20
Shef-LMS 01 ws Leiomyosarcoma p62 22 118 (80–134) 31 11 7–21
Shef-MFS 02 Myxoﬁbrosarcoma p2 15 77 (42–105) 24 15 11–26
aNormalised for 2n karyotype by multiplying observed SCE counts by 46 and then dividing by observed chromosome number. bTumour was previously
treated with radiotherapy prior to resection. cSCE analysis was repeated after further in vitro culture.
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those of the commercial lines. All nine primary sarcoma cell
lines had SCE levels that were higher than the normal range
with at least 7 endogenous SCEs seen within each metaphase
chromosome spread and median SCE counts of between 10
and 18 per 2n metaphase spread. *e elevated SCE levels
were independent of chromosome number and STS subtype
(Table 1 and Figure 2).
In the four primary sarcoma cell lines, where SCE
analysis was repeated after approximately 4 months, the
additional 5 to 15 culture passages did not appear to sig-
niﬁcantly aﬀect the SCE levels. Furthermore, it was in-
teresting to note that in Shef-UPS 02 and Shef-UPS 03,
despite an increase in the median and range of the chro-
mosome numbers observed between the two time points,
their SCE frequency remained at about the same level when
normalised for a diploid karyotype (Table 1).
3.3. Endogenous cH2AX Foci Are Increased in Sarcoma Cells
but Do Not Correlate with SCE Levels. Detection of phos-
phorylated H2AX (cH2AX) foci by immunoﬂuorescence
was used for the detection of endogenous DNA double-
strand breaks (DSBs). We performed cH2AX analysis on
eight primary STS cell lines.*e osteosarcoma (U-2 OS) and
retinal epithelial (hTERT-RPE1) cell lines were used as
tumour and nontumour cell line controls, respectively. *e
results were correlated with the corresponding endogenous
SCE levels and are summarised in Figure 3.
*e normal cell line hTERT-RPE1 showed very little
evidence of endogenous DNA DSB with no cells showing
more than 10 cH2AX foci. Among all the sarcoma cell lines,
however, at least 10% of cells showed more than 10 cH2AX
foci. *ere was no relationship between the SCE levels and
frequency of cH2AX foci among the sarcoma cell lines
(Spearman’s r2 � 0.029; p � 0.99). U-2 OS, the osteosar-
coma cell line, that had almost double the number of SCEs
seen among the other sarcoma cell lines surprisingly had
relatively few cH2AX foci (Figure 3). Conversely, the highest
frequency of cH2AX foci (>65% of cells showing >10 foci)
was observed in dediﬀerentiated liposarcoma cell lines Shef-
DDLPS 01 and Shef-DDLPS 02, whose SCE levels were only
moderately elevated with medians of 13 and 14 per 2n
metaphase spread, respectively (Table 1 and Figure 2). In-
terestingly, one of these two cell lines was derived from
a dediﬀerentiated liposarcoma that prior to excision was
treated with radiotherapy to which the patient had a sig-
niﬁcant radiologic and histologic response [27]. Another
notable observation was the more than threefold diﬀerence
in the frequency of cells showing >10 cH2AX foci between
w1 and ws variants of Shef-LMS 01, which had very similar
SCE levels (Figure 3).
4. Discussion
Reports of SCE analysis performed directly on solid tumour
cells are rare in the published literature. Precise timing of
BrdU exposure and chromosome harvest is largely un-
predictable in many solid tumour cell lines, but especially so
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Figure 2: Frequency of sister chromatid exchange (SCE) in sar-
coma cell lines. Normal and low SCE controls (clear boxes) had
SCE frequency within the expected normal range (6–8 per 2n cell).
All the sarcoma cell lines show SCE frequency above the normal
range with primary sarcoma cells (dark grey boxes) comparable to
established commercially available sarcoma cells (light grey boxes).
SCE counts were normalised for diploid (2n) karyotype by mul-
tiplying the number of observed SCE by 46 and then dividing by the
observed chromosome number. Boxes represent the interquartile
range with horizontal line at median, while whiskers represent the
minimum and maximum enumerated SCEs derived from 10 to 30
metaphase chromosome spreads.
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Figure 3: Endogenous cH2AX foci and sister chromatid exchange
analysis in sarcoma cell lines. No relationship was seen between the
frequency of endogenous cH2AX foci (bars) and SCE (corre-
sponding black dots) among sarcoma cell lines (Spearman’s
r2 � 0.029; p � 0.99). All nine cell lines however showed high
frequency of endogenous cH2AX foci and SCE, compared with
nontumour control hTERT-RPE1 cells that had no cells with more
than 10 endogenous cH2AX foci. Bars plotted along the left y-axis
represent the percentage of 100 randomly selected cells in each
corresponding cell line with >10 endogenous cH2AX foci, and data
are shown as the mean of 3 independent repeat experiments. Black
dots plotted along the right y-axis represent the median SCE counts
from 10 to 30 metaphase chromosome spreads. *e SCE counts
were normalised for a diploid (2n) karyotype by multiplying the
number of observed SCE by 46 and then dividing by the observed
chromosome number.
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among primary cell cultures, such as those used in this study.
To our knowledge, this is the ﬁrst report of combined SCE
and cH2AX analysis for the measurement of genomic in-
stability in sarcoma cells.
*e nine primary tumour cell lines in this study have
previously been shown to possess very complex karyotypes
[27]. It was therefore not surprising that the endogenous
SCE levels observed were consistently higher than the
normal range even after correction for aneuploidy (Table 1
and Figure 2). Given the magnitude of genomic perturbation
that is pervasive among these tumours, it was expected that
the SCE frequencies would be even higher than those ob-
served. However, when compared with other cancers, these
results are concordant with previous studies that reported
high SCE frequency in tumour cells obtained from the
peripheral circulation in leukaemia patients as well as
lymphoma, melanoma, breast, and colon cancer cell lines
[23–26].
In support of the genomic instability suggested by their
elevated SCE levels, cH2AX analysis also showed high levels
of endogenous DNA DSBs among all the sarcoma cell lines
compared with normal control cells (Figure 3). *ese results
are in line with those of Yu et al., as well as more recent
studies that demonstrated elevated endogenous cH2AX foci
among 17 cancer cell lines from the NCI-60 panel with
20–95% of cells showing foci [33, 34]. In the same study, they
also found that the number of foci seen correlated with the
magnitude of karyotypic complexity of the cell lines eval-
uated, which supports our ﬁnding of high SCE levels among
our cell lines that are derived from soft tissue sarcomas with
very complex karyotypes. However, it does not account for
the signiﬁcant diﬀerence in the frequency of endogenous
DNADSBs observed between the two variants (ws and w1) of
the leiomyosarcoma cell line Shef-LMS 01 (Figure 3) even
though they had very similar average SCE frequency and
chromosome number (Figure 2 and Table 1). Endogenous
cH2AX foci are believed to represent DNA DSBs resulting
from replication fork collapse/stress during the cell cycle
[11], while SCE represents their subsequent repair. One
possible explanation is that the cellular capacity for DNA
repair by homologous recombination in these two tumour
cell clones is ﬁnite resulting in their similar SCE levels
despite the signiﬁcant diﬀerence in the endogenous DSBs.
*e remaining DNA damage in the ws variant may have
been repaired via other cellular mechanisms such as non-
homologous end-joining (NHEJ), which is also preceded by
cH2AX formation [35, 36], or perhaps a relatively higher
proportion of the cells were directed towards apoptosis. *is
hypothesis warrants further investigation to evaluate both
endogenous and induced (in response to IR and other
genotoxic agents) apoptosis and NHEJ among these cell
lines.
Similarly, there was no correlation demonstrated be-
tween the frequency of SCE and endogenous H2AX foci
among all the cell lines in this study when evaluated by
Spearman’s test. An illustrative example was the dediﬀer-
entiated liposarcoma cell line Shef-DDLPS 02 that had high
endogenous cH2AX foci but relatively low SCE counts
(Figure 3). A possible explanation is that, despite the
evidence of high frequency of DNA DSBs evidenced by the
number of cH2AX foci, the tumour cells have a poor ability
to perform subsequent DNA repair by homologous re-
combination resulting in paradoxically low SCE frequency.
*is theory is supported by the good response (over 90%
necrosis) to neoadjuvant radiotherapy that was seen on
histologic examination of the parent tumour for this cell
line (data not shown). Conversely, the U-2 OS cell line
which had approximately double the SCE frequency ob-
served in the other sarcoma cell lines had relatively few
endogenous cH2AX foci (Figure 3), an overall picture that
would suggest highly eﬃcient DNA repair. Given that U-2
OS is an osteosarcoma cell line and that this tumour
subtype is known to be relatively resistant to radiotherapy,
the results are not altogether surprising. Again, further
studies to evaluate the cH2AX foci, SCE counts, and ap-
optotic response of these cell lines to ionising radiation (IR)
would be useful to further elucidate the impact of en-
dogenous genomic instability on treatment response in
these sarcomas.
Temporal changes in genomic instability with in vitro
culture were assessed when SCE analysis of four primary cell
lines was repeated after 4 months (Table 1). *e results
showed that the SCE frequency remained around the same
level with time in culture, suggesting that the magnitude of
genetic instability remained fairly constant in these primary
sarcoma cells. However, according to the clonal evolution
theory of cancer, longer duration in culture permits the
accumulation of further genomic aberrations with time, and
this is supported by an increase in the chromosome number
observed in these cell lines with time and their acquisition of
some new copy number abnormalities [27]. Perhaps,
therefore, an alternative DNA repair mechanism with less
accuracy than homologous recombination and not repre-
sented by SCE analysis is utilised by these tumour cells
resulting in their continued accumulation of genomic ab-
errations. Once again, further longitudinal studies with
evaluation of various alternative DNA repair mechanisms
are warranted.
5. Conclusions
*is study is the ﬁrst of its kind in sarcomas and conﬁrms
that genomic instability is indeed characteristic of these
tumours. It also highlights potential inter- and intratumour
diﬀerences in DNA damage and/or responses as well as
potential markers for the prediction of response to radio-
therapy among these rare and heterogeneous tumours.
Overall, the data, while not suﬃcient to make ﬁrm con-
clusions about their utility as biomarkers, suggest that there
is still much to understand about the relationship between
cH2AX and SCE in sarcomas. Given that these tumours are
so heterogeneous, it is likely that a number of explanations
could exist including highly eﬃcient homologous re-
combination, increased apoptosis, or alternative DNA repair
pathways. Importantly, the stage is set for further studies
that will improve our understanding of the mechanisms for
genomic instability among sarcomas and how to utilise this
for choosing appropriate treatments.
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